Taking stock of the drug industry, from the lab to the medicine chestJuly 12, 2024Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Adobe Opinion: Adaptive trial designs will increase clinical trial speed, safety, and effectiveness Adaptive trials can be complex, but hold immense potential for accelerating the pace of life science innovation. By Raviv Pryluk and Mike Walsh CAR-T cell therapy's complications, as well as its benefits, become clearer in 'flurry' of cancer studies The FDA's concern about the therapy's possible link to secondary cancers has yielded a flurry of studies, and no smoking gun. By Alia Sajani and Angus Chen Listen: Biotech layoffs, founder-focused VC, & a big pharma exit STAT's West Coast biotech reporter Jonathan Wosen joins "The Readout LOUD" to discuss what's driving workforce cuts. By Allison DeAngelis, Adam Feuerstein, and Elaine Chen Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2024, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments